Table 1 Early clinical trials evaluating inotuzumab ozogamicin monotherapy in adults with relapsed/refractory B-cell ALL

Kantarjian H et al. 2013 [11]

(Phase II)

90

39.5 [4–84]

• Patients #1–49: 1.3–1.8 mg/m² once per cycle

• Patients #50–90: 0.8 mg/m² on D1, 0.5 mg/m² on D8 and D15 each cycle

58%

40%

6.2 months

17%^a

Deangelo DJ et al. 2017 [12]

(Phase I/II)

72

45 [20–79]

• Induction: 0.8 mg/m² on D1, 0.5 mg/m² on D8 and D15 each cycle^b

• Once in CR/CRi: 0.8 mg/m² on D1, 0.4 mg/m² on D8 and D15 each cycle

68%

33%

7.4 months

6%

Kantarjian H et al. 2016 [1]

(Phase III)

164^c

47 [18–78]

• Induction: 0.8 mg/m² on D1, 0.5 mg/m² on D8 and D15 each cycle

• Once in CR/CRi: 0.5 mg/m² on D1, D8 and D15 each cycle

80.7%

41%

7.7 months

11%